Credibility Index › UiPath (PATH) › Q2'26

UiPath (PATH) Q2'26 Earnings Call

Management-credibility review · call 2025-09-04
B+
Overall grade
B
Financial quality
The sleeper story is **AgenTic monetization happening now** despite management's conservative 2026 guidance - 1M agent runs and consumption pricing suggest they're sandbagging ahead of 2027. Federal normalization removes the biggest growth headwind, but the binding constraint is **existing customer expansion**, not new product adoption. As Dines said, 'The future isn't about choosing between agents and automation. It's about combining them.' My view changes if net new ARR doesn't accelerate meaningfully in Q3 despite federal recovery and AgenTic traction.

The 30-second version

What changed this quarter

MetricPriorThis quarter
Revenue$357M (+6% YoY)$362M (+14% YoY)
ARR$1.693B (+12% YoY)$1.723B (+11% YoY)
Net New ARR$27M$31M
Cloud ARRNot disclosed$1.080B (+25% YoY)
DBNR108%108%
Non-GAAP Op Income$70M (20% margin)$62M (17% margin)
$100K+ Customers2,3652,432
$1M+ Customers316320

Accountability tracked

7 new promises made4 narrative shifts flagged6 prior promises graded
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Subscribe to Call Sheet Daily →
Other PATH quarters: Q1'26 · Q3'26 · Q4'26
Full PATH credibility scorecard →
About Research ↗ · Credibility Index · Missed Promises · Screens · 13F Holdings · Subscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Grades, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.